# L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

> **NCT03982160** · PHASE4 · RECRUITING · sponsor: **The University of Texas at Arlington** · enrollment: 15 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** L-Arginine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03982160
- **Lead sponsor:** The University of Texas at Arlington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982160, "L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03982160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*